150mg A Alectinib is a medication used to treat a specific type of lung cancer called non-small cell lung cancer (NSCLC). It is classified as a tyrosine kinase inhibitor (TKI) and is primarily used for the treatment of NSCLC that has a specific genetic mutation known as anaplastic lymphoma kinase (ALK) gene rearrangement. The drug is generally prescribed when the lung cancer has spread to other parts of the body (metastatic) or when the cancer has relapsed after previous treatments. 150mg A Alectinib is typically taken orally in capsule form and should be taken as directed by a healthcare professional. The dosage and duration of treatment will depend on the specific patient's condition and response to the medication.